BioXcel Therapeutics/$BTAI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioXcel Therapeutics
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Ticker
$BTAI
Sector
Primary listing
Employees
29
Headquarters
Website
BTAI Metrics
BasicAdvanced
$37m
-
-$4.46
0.31
-
Price and volume
Market cap
$37m
Beta
0.31
52-week high
$8.08
52-week low
$1.01
Average daily volume
663k
Financial strength
Current ratio
0.617
Quick ratio
0.316
Long term debt to equity
-73.769
Total debt to equity
-95.022
Interest coverage (TTM)
-2.93%
Profitability
EBITDA (TTM)
-50.109
Gross margin (TTM)
36.32%
Net profit margin (TTM)
-11,078.53%
Operating margin (TTM)
-7,410.44%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-86.77%
Return on equity (TTM)
76.98%
Valuation
Price to revenue (TTM)
29.81
Price to book
-0.31
Price to tangible book (TTM)
-0.31
Price to free cash flow (TTM)
-0.353
Free cash flow yield (TTM)
-283.08%
Free cash flow per share (TTM)
-3.397
Growth
Revenue change (TTM)
-63.28%
Earnings per share change (TTM)
-63.70%
3-year revenue growth (CAGR)
5.38%
3-year earnings per share growth (CAGR)
-65.25%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs